Ascendis Pharma A/S
ASND
$158.26
-$3.27-2.02%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 30.00% | 56.16% | 38.23% | 10.93% | -19.59% |
| Total Depreciation and Amortization | -1.59% | -11.69% | -6.85% | -6.59% | -0.31% |
| Total Amortization of Deferred Charges | -- | -4.27% | -- | -- | -- |
| Total Other Non-Cash Items | -70.49% | -10.59% | -199.51% | 3,393.96% | 677.93% |
| Change in Net Operating Assets | 182.64% | -300.02% | 854.78% | 55.24% | -129.54% |
| Cash from Operations | 86.34% | -103.24% | 54.54% | 60.41% | 30.07% |
| Capital Expenditure | -242.50% | -758.70% | 51.67% | 23.84% | 81.44% |
| Sale of Property, Plant, and Equipment | -- | -100.00% | -100.00% | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -99.47% | -100.16% | -100.00% | -96.48% |
| Cash from Investing | -109.52% | -105.72% | -102.29% | -98.72% | -96.56% |
| Total Debt Issued | -- | 100.00% | -4.02% | -- | -- |
| Total Debt Repaid | -10.05% | -7.75% | -7.41% | -12.04% | -8.49% |
| Issuance of Common Stock | -34.77% | 1,006.29% | 4,687.34% | 75.48% | 1,036.60% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -194.84% | 101.42% | 201.47% | -5.14% | 2,756.71% |
| Foreign Exchange rate Adjustments | -303.90% | 394.45% | -172.17% | 12.17% | 164.66% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 43.91% | -33.03% | 687.55% | 43.16% | -228.83% |